Patient life engagement in the context of MDD treatment is a new exploratory endpoint
MONTREAL, Sept. 29, 2022 /CNW/ - Otsuka Canada Pharmaceutical Inc. and Lundbeck Canada Inc., together with their global teams, presented the headline results of ENGAGE, a Canadian Phase IV study in major depressive disorder (MDD) at the Psych Congress in New Orleans on September 18 and 19.
One of the co-primary endpoints of the study on adjunctive brexpiprazole in adults with MDD and inadequate response to antidepressant treatment (ADT) was a new exploratory outcome focusing on positive health aspects across emotional, physical, social, and cognitive domains, referred to as patient life engagement.
Otsuka and Lundbeck sought to advance the understanding of patient-focused outcomes in MDD treatment after hearing the voice of patients who proactively called into the companies' call centres to share their personal experiences with brexpiprazole treatment. These spontaneous reports prompted Otsuka and Lundbeck to further explore the experience of patients living with MDD, including their priorities and preferences, and attempt to translate the qualitative themes of the patient feedback into quantitative scientific data. The importance of incorporating the patients' perspective into individual treatment plans has been underscored by the finding that clinician treatment goals are often different than those of their patients.
"My patients are well informed and want to discuss their hopes and goals for treatment success. A collaborative effort to determine what my patients want as goals of Depression treatment has led to a more satisfying, connected relationship with better functional and wellbeing outcomes. This new Canadian study validates what I have been seeing in my practice," notes Dr. Pratap Chokka, a psychiatrist based in Edmonton.
The ENGAGE study was designed in collaboration with a group of Canadian experts and conducted at 15 sites across Canada, with both psychiatrists and primary care physicians as principal investigators in adults with MDD and inadequate response to ADT. The study enrolled 122 Canadian participants between April 2021 and March 2022, and 111 participants completed the 8-week study.
Patient life engagement in the context of MDD treatment is a new exploratory endpoint not included in the Canadian label and remains to be further validated. Otsuka and Lundbeck will continue to explore this and further innovative patient-relevant outcome measures in the treatment of MDD and other psychiatric conditions, in collaboration with the patient community and clinical experts.
REXULTI (brexpiprazole) is indicated for:
Treatment of schizophrenia in adults.
Use as an adjunct to antidepressants for the treatment of major depressive disorder (MDD) in adult patients with an inadequate response to prior antidepressant treatments during the current episode.
About Otsuka Canada
OCPI is an innovative, fast-growing health care company that commercializes novel medicines in Canada. OCPI aims to improve the quality of life and health of patients through its
commitments to neuroscience, cardio-renal, and nephrology. OCPI was established in 2010, with headquarters in Saint-Laurent, Quebec.
OCPI is part of Otsuka Pharmaceutical Co., Ltd., a global healthcare company with the corporate philosophy: Otsuka – people creating new products for better health worldwide. Otsuka Pharmaceutical Co., Ltd., researches, develops, manufactures, and markets innovative and original products, with a focus on pharmaceutical products for the treatment of diseases and nutraceutical products for the maintenance of everyday health.
Otsuka Pharmaceutical is a wholly owned subsidiary of Otsuka Holdings Co., Ltd., based in Tokyo, Japan. The Otsuka group of companies employs approximately 47,000 people worldwide and had consolidated sales of approximately USD 13.6 billion in 2021.
About Lundbeck Canada
Since 1995, Lundbeck Canada has been striving to improve the lives of Canadians living with brain diseases. As a subsidiary of H. Lundbeck A/S, a global pharmaceutical company specialized in brain diseases, we benefit from more than 70 years at the forefront of neuroscience research. We are tirelessly dedicated to restoring brain health, so every person can be their best. We are committed to fighting stigma and discrimination against people living with brain diseases and advocating for broader social acceptance of people with brain health conditions. Lundbeck's research programs tackle some of the most complex challenges in neuroscience, and our pipeline is focused on bringing forward transformative treatments for brain diseases for which there are few, if any therapeutic options.
SOURCE Otsuka Canada Pharmaceutical Inc.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/September2022/29/c0052.html